Human monoclonal antibodies against Staphylococcus aureus surface antigens recognize in vitro and in vivo biofilm
de Vor, Lisanne; van Dijk, Bruce; van Kessel, Kok; Kavanaugh, Jeffrey S.; de Haas, Carla; Aerts, Piet C.; Viveen, Marco C.; Boel, Edwin C.; Fluit, Ad C.; Kwiecinski, Jakub M.; Krijger, Gerard C.; Ramakers, Ruud M.; Beekman, Freek J.; Dadachova, Ekaterina; Lam, Marnix G. E. H.; Vogely, H. Charles; van der Wal, Bart C. H.; van Strijp, Jos A. G.; Horswill, Alexander R.; Weinans, Harrie; Rooijakkers, Suzan H. M.
(2022) eLife, volume 11, pp. 1 - 25
(Article)
Abstract
Implant-associated Staphylococcus aureus infections are difficult to treat because of biofilm formation. Bacteria in a biofilm are often insensitive to antibiotics and host immunity. Monoclonal antibodies (mAbs) could provide an alternative approach to improve the diagnosis and potential treatment of biofilm-related infections. Here, we show that mAbs targeting common surface
... read more
components of S. aureus can recognize clinically relevant biofilm types. The mAbs were also shown to bind a collection of clinical isolates derived from different biofilm-associated infections (endocarditis, prosthetic joint, catheter). We identify two groups of antibodies: one group that uniquely binds S. aureus in biofilm state and one that recognizes S. aureus in both biofilm and planktonic state. Furthermore, we show that a mAb recognizing wall teichoic acid (clone 4497) specifically localizes to a subcutaneously implanted pre-colonized catheter in mice. In conclusion, we demonstrate the capacity of several human mAbs to detect S. aureus biofilms in vitro and in vivo.
show less
Download/Full Text
Keywords: General Neuroscience, General Biochemistry,Genetics and Molecular Biology, General Immunology and Microbiology
ISSN: 2050-084X
Publisher: eLife Sciences Publications
Note: Funding Information: The authors greatly thank Reindert Nijland (Department of Animal Sciences, Wageningen University and Research, Wageningen, The Netherlands) and Fernanda Paganelli (Department of Medical Microbiology, UMC Utrecht) for assistance with biofilm work; Miquel Ekkelenkamp and Sebastian van Marm (Department of Medical Microbiology, UMC Utrecht) for providing S. aureus clinical isolates; Astrid Hendriks (Department of Medical Microbiology, UMC Utrecht), Nina van Sorge (Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, The Netherlands), and Jeroen Codee (Leiden Institute of Chemistry, Leiden University, The Netherlands) for providing WTA glycosylated beads; Frank Beurskens (Genmab BV, Utrecht, The Netherlands) for help with selection of mAbs; Sonja von Aulock and Siegfried Morath (Department of Biochemical Pharmacology, University of Konstanz, Konstanz, Germany) for providing LTA preparates. LdV and BvD were supported by a grant from Health~Holland (LSHM17026 to JvS and HW). FJB and RMR were supported by the research grant QUARAT: Quantitative Universal Radiotracer Tomography (TTW16885, Dutch Research Council (NWO)). ARH was supported by a merit award (BX002711) from the U.S. Department of Veteran Affairs and grant AI083211 from the National Institutes of Health. Funding Information: The authors greatly thank Reindert Nijland (Department of Animal Sciences, Wageningen University and Research, Wageningen, The Netherlands) and Fernanda Paganelli (Department of Medical Microbiology, UMC Utrecht) for assistance with biofilm work; Miquel Ekkelenkamp and Sebastian van Marm (Department of Medical Microbiology, UMC Utrecht) for providing S. aureus clinical isolates; Astrid Hendriks (Department of Medical Microbiology, UMC Utrecht), Nina van Sorge (Department of Medical Microbiology and Infection Prevention, Amsterdam UMC, The Netherlands), and Jeroen Codee (Leiden Institute of Chemistry, Leiden University, The Netherlands) for providing WTA glyco-sylated beads; Frank Beurskens (Genmab BV, Utrecht, The Netherlands) for help with selection of mAbs; Sonja von Aulock and Siegfried Morath (Department of Biochemical Pharmacology, University of Konstanz, Konstanz, Germany) for providing LTA preparates. LdV and BvD were supported by a grant from Health~Holland (LSHM17026 to JvS and HW). FJB and RMR were supported by the research grant QUARAT: Quantitative Universal Radiotracer Tomography (TTW16885, Dutch Research Council (NWO)). ARH was supported by a merit award (BX002711) from the U.S. Department of Veteran Affairs and grant AI083211 from the National Institutes of Health. Publisher Copyright: © de Vor et al.
(Peer reviewed)
